AUBAGNE, France & GOETTINGEN, Germany--(BUSINESS WIRE)--Regulatory News:
(Paris:DIM)
Sartorius Stedim Biotech Group’s Investor Relations News concerning the first quarter 2017 is now available at
http://www.sartorius-france.fr/en/company/investor-relations/sartorius-stedim-biotech-sa/
It contains the following information:
- Business development for the first quarter 2017 and the full-year 2017 forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended March 31, 2017
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2016, the company employed approx. 4,700 people, and earned sales revenue of 1,052 million euros.
